Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Paul Ausick | Jun 24, 2014 at 1:15 PM EDT

The Real Attraction to Vertex After Cystic Fibrosis Success

Vertex Pharmaceuticals has reported that two Phase 3 studies of its lumacaftor cystic fibrosis drug in combination with its Kalydeco…

Jon C. Ogg | Jun 20, 2014 at 8:55 AM EDT

As Antibiotics Stop Working, Five Biotechs Seek Cures

ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some…

Jon C. Ogg | Jun 19, 2014 at 2:05 PM EDT

Will Celgene Trigger Other Biotech Stock Splits?

Celgene has decided to join the stock split game. Even though stock splits change nothing fundamentally, 24/7 Wall St. would…

Trey Thoelcke | Jun 19, 2014 at 9:05 AM EDT

The Affordable Care Act Is Working Big for These Six Companies

The UBS team highlights six top stocks that are seeing increased prescription volume since the implementation of parts of the…

Jon C. Ogg | Jun 18, 2014 at 10:45 AM EDT

Why Insmed Could Still Double

Insmed shares screamed higher on Wednesday. The driver was an SEC filing stating the FDA had granted Arikace breakthrough therapy…

Paul Ausick | Jun 16, 2014 at 7:50 AM EDT

Medtronic and Covidien Deal Is All About Taxes and Dividends

The $42.9 billion merger between medical device makers Medtronic and Covidien was officially confirmed early Monday morning. The deal is…

Douglas A. McIntyre | Jun 16, 2014 at 6:28 AM EDT

U.S. Health Care: Most Expensive, Least Effective

ThinkstockThe U.S. health care system is the most expensive among large developed nations. And it produces the worst results. Medical…

Jon C. Ogg | Jun 14, 2014 at 9:20 AM EDT

The MannKind Lifeline Lights Up

MannKind is just about a month away from the FDA decision on Afrezza as the first inhalable insulin treatment for…

Jon C. Ogg | Jun 11, 2014 at 5:02 PM EDT

Orexigen Irony: No VIVUS Bounce

ThinkstockVIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America’s ballooning waistline is reaching a…

Trey Thoelcke | Jun 11, 2014 at 10:15 AM EDT

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in…

Jon C. Ogg | Jun 11, 2014 at 6:50 AM EDT

Short Sellers Remain Vigilant Against Top Biotech Stocks

ThinkstockShort sellers have many reasons to bet against a stock, some of which are hedging or part of a larger…

Jon C. Ogg | Jun 10, 2014 at 8:20 AM EDT

After Idenix: The Next Four Biotech Buyout Candidates

Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at…

Trey Thoelcke | Jun 9, 2014 at 9:25 AM EDT

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally…

Jon C. Ogg | Jun 6, 2014 at 11:20 AM EDT

As GW Pharma Gets Fast Track, Is FDA More Open to Medical Marijuana?

GW Pharmaceuticals was one of the stocks surging on Friday, on news that the U.S. Food and Drug Administration (FDA)…

Jon C. Ogg | Jun 5, 2014 at 11:15 AM EDT

Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients

Halozyme Therapeutics saw its stock surge on Thursday on news reports that the FDA has removed its clinical hold on…

1 … 285 286 287 288 289 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

The Real Attraction to Vertex After Cystic Fibrosis Success

As Antibiotics Stop Working, Five Biotechs Seek Cures

Will Celgene Trigger Other Biotech Stock Splits?

The Affordable Care Act Is Working Big for These Six Companies

Why Insmed Could Still Double

Medtronic and Covidien Deal Is All About Taxes and Dividends

U.S. Health Care: Most Expensive, Least Effective

The MannKind Lifeline Lights Up

Orexigen Irony: No VIVUS Bounce

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

Short Sellers Remain Vigilant Against Top Biotech Stocks

After Idenix: The Next Four Biotech Buyout Candidates

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

As GW Pharma Gets Fast Track, Is FDA More Open to Medical Marijuana?

Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

Health and Healthcare Articles

All Health and Healthcare Articles

The Real Attraction to Vertex After Cystic Fibrosis Success

As Antibiotics Stop Working, Five Biotechs Seek Cures

Will Celgene Trigger Other Biotech Stock Splits?

The Affordable Care Act Is Working Big for These Six Companies

Why Insmed Could Still Double

Medtronic and Covidien Deal Is All About Taxes and Dividends

U.S. Health Care: Most Expensive, Least Effective

The MannKind Lifeline Lights Up

Orexigen Irony: No VIVUS Bounce

Upcoming Binary Events Could Lift These Health Care Stocks Much Higher

Short Sellers Remain Vigilant Against Top Biotech Stocks

After Idenix: The Next Four Biotech Buyout Candidates

Large Cap Biotech Stocks to Buy Leading the Comeback Rally

As GW Pharma Gets Fast Track, Is FDA More Open to Medical Marijuana?

Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients

A $620,000 Portfolio That Pays More Than the Average Social Worker’s Salary

Prediction: Pfizer Stock Will Double on This Date

SMH ETF Investors: Watch Hyperscaler Capex Guidance at July Earnings Calls

Featured Reads

A $620,000 Portfolio That Pays More Than the Average Social Worker's Salary

The Average American Has Worked for 6 Employers and 23% Still Have Multiple Old Retirement Accounts, Fidelity's 2026 Study Finds